Fennec Pharmaceuticals (TSE:FRX) Reaches New 1-Year High - Here's What Happened

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as C$12.15 and last traded at C$12.14, with a volume of 809 shares traded. The stock had previously closed at C$11.89.

Fennec Pharmaceuticals Stock Up 2.3%

The business has a 50 day moving average of C$10.37 and a 200-day moving average of C$9.34. The stock has a market cap of C$234.50 million, a PE ratio of -205.99 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

Insider Buying and Selling

In related news, Senior Officer Robert Christopher Andrade acquired 8,220 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, with a total value of C$57,433.14. Also, Director Jeffrey Hackman acquired 15,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, with a total value of C$146,580.00. Insiders have sold 38,076 shares of company stock worth $391,650 in the last quarter. 16.20% of the stock is owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.